Analyst Ratings For CytomX Therapeutics (NASDAQ:CTMX)
Today, Jefferies Group raised its price target on CytomX Therapeutics (NASDAQ:CTMX) to per share.
Some recent analyst ratings include
- 1/5/2018-Citigroup initiated coverage with a Buy rating.
- 10/5/2017-Cowen Reiterated Rating of Outperform.
- 10/4/2017-Oppenheimer Reiterated Rating of Hold.
Recent Insider Trading Activity For CytomX Therapeutics (NASDAQ:CTMX)
CytomX Therapeutics (NASDAQ:CTMX) has insider ownership of 4.70% and institutional ownership of 78.50%.
- On 3/2/2018 Debanjan Ray, CFO, sold 33,000 with an average share price of $29.99 per share and the total transaction amounting to $989,670.00.
- On 3/2/2018 Frederick W Gluck, Director, sold 16,181 with an average share price of $30.00 per share and the total transaction amounting to $485,430.00.
- On 3/2/2018 Rachel Humphrey, Insider, sold 16,160 with an average share price of $30.00 per share and the total transaction amounting to $484,800.00.
- On 2/28/2018 Frederick W Gluck, Director, sold 3,819 with an average share price of $30.00 per share and the total transaction amounting to $114,570.00.
- On 2/28/2018 Rachel Humphrey, Insider, sold 23,840 with an average share price of $30.00 per share and the total transaction amounting to $715,200.00.
- On 2/1/2018 Debanjan Ray, CFO, sold 2,548 with an average share price of $26.69 per share and the total transaction amounting to $68,006.12.
- On 1/5/2018 Frederick W Gluck, Director, sold 10,000 with an average share price of $25.01 per share and the total transaction amounting to $250,100.00.
Recent Trading Activity for CytomX Therapeutics (NASDAQ:CTMX)
Shares of CytomX Therapeutics closed the previous trading session at 32.67 down -1.20 3.54% with shares trading hands.